In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
Veeda Clinical Research Limited, a full-service contract research organization (CRO) with a proven record of drug development success, announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology. 27 March 2024
Pharmaceutical
Not-for-profit research partnership TB Alliance has won a A$17 million grant from the Australian government to continue its work combating tuberculosis. 26 March 2024
Biotechnology
US clinical-state biotech Avenzo Therapeutics today announced the closing of an oversubscribed $150 million Series A-1 financing. 26 March 2024
Pharmaceutical
German pain specialist Grünenthal has released its 2023 full-year results, announcing a double-digit revenue growth. 26 March 2024
Biotechnology
US mRNA specialist Moderna this morning announced that mRNA1283, its next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase III clinical trial. 26 March 2024
Pharmaceutical
Cohance Lifesciences and Suven Pharma are to merge, creating one of India's largest integrated contract development and manufacturing organization (CDMO) players. 26 March 2024
Biotechnology
Poseida Therapeutics has appointed Syed Rizvi as chief medical officer. 26 March 2024
Pharmaceutical
New York-based Nuvation Bio, a biopharma tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, is to buy AnHeart Therapeutics. 26 March 2024
Pharmaceutical
US privately-held biopharma Pharmazz and Dr Reddy's Laboratories have enter into licensing agreement to market first-in-class centhaquine (trade name Lyfaquin) for hypovolemic shock in India. 26 March 2024
Biotechnology
Japanese drug major Astellas Pharma today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Vyloy (zolbetuximab). 26 March 2024
Pharmaceutical
New York-based Axsome Therapeutics has announced positive results from the Phase III SYMPHONY trial of reboxetine. 26 March 2024
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has picked up an approval for Vabysmo (faricimab) in its home country. 26 March 2024
Pharmaceutical
Drug sales in the Russian market are steadily growing, while last year the overall retail sales increased by 8% year-on-year basis to 1.5 trillion roubles $16.2 billion), according to latest data, provided by the Russian pharmaceutical analytics agency RNC Pharma, reports The Pharma Letter’s local correspondent. 26 March 2024
Biotechnology
US pharma major AbbVie is to acquire Landos Biopharma, news that sent the latter company’s share price rocketing by 165% during Monday morning’s trading. 25 March 2024
Biotechnology
US biotech Regeneron Pharmaceuticals was trading nearly 1% lower at lunchtime on Monday. 25 March 2024
Pharmaceutical
Pharmaceutical companies from so-called “unfriendly” countries for Russia will be required to coordinate transactions for the sale of brands and means of individualization in the country’s pharmaceutical market to local legal entities with the specially established state regulator in order to tighten a control for them and prevent the illegal withdrawal funds from the local market. 25 March 2024
Pharmaceutical
In the fragmented and complex US healthcare system, the market value of pharmacy benefit managers (PBM) has reached new heights. 25 March 2024
Biotechnology
In California, an artificial intelligence-based protein design company called Profluent has added $35 million to its financing, with money being put forward by Spark Capital, among others. 25 March 2024
Biotechnology
Shares of US clinical-stage drugmaker Moleculin Biotech were going through the roof, leaping 1,228% to $6.11 in early trading, as the company updated on its lead candidate’ 25 March 2024
Biotechnology
US biotech Verge Genomics and Spanish rare neurological disorders specialist Ferrer have signed a strategic collaboration. 25 March 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze